Adjuvant chemotherapy for colorectal cancer

Demols, A.; Laethem, Jean‐Luc Van

doi:10.1007/s11894-002-0013-3

Cited by 12 publications

(7 citation statements)

References 46 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The difference might be due to a significantly higher frequency of cardiovascular comorbidity in group I (p = 0.01) or the lack of sensible palliative or curative operative therapy options. Adjuvant treatment procedures have become Falch/Kratt/Beckert/Kirschniak/Zieker/ Königsrainer/Löb/Hartmann/ Königsrainer/Brücher the standard approach in patients with locally advanced colorectal carcinoma (stage III and some stage II lesions) [27,28]. However, despite the significant increase in the survival period that can be achieved [29], these procedures are still withheld from many patients for reasons of age or comorbid conditions [30,31].…”

Section: Discussionmentioning

confidence: 99%

Surgery of Colorectal Carcinoma in Patients Aged over 80

Falch¹,

Kratt²,

Beckert³

et al. 2009

Oncol Res Treat

View full text Add to dashboard Cite

Background: The incidence of colorectal carcinoma increases rapidly in aged patients. We investigated retrospectively the differences in treatment relative to the patients’ age. Patients and Methods: A total of 394 patients with colorectal carcinoma (group I: ≥80 years, n = 197; group II: 60–79 years, n = 197) were analyzed in an average period of 4 years in relation to surgery, comorbidities, postoperative morbidity, mortality, survival and recurrence. Results: Patients ≥80 years had a significantly higher rate of comorbid conditions (p = 0.04; cardiovascular, p = 0.01; diabetes mellitus, p < 0.05) and more carcinomas in the sigmoid/rectum (72% vs. 67%; p < 0.05). Tumor stage, R0 resection rate, and overall complication rate were not influenced by age. The 30-day mortality rate was significantly higher in group I (12% vs. 3%; p = 0.02). Emergency surgical procedures were required significantly more often in group I (14%) than in group II (5%; p = 0.003). The 5-year survival rate among patients in group I was 30.1% compared to 50.5% among patients in group II (p < 0.0001). Conclusions: Elderly patients have a higher rate of comorbidity and a higher postoperative 30-day mortality rate. Tumor stage, R0 resection rate, and overall postoperative complication rate do not appear to be influenced by age. The higher rate of emergency operations on patients ≥80 years is associated with the higher 30day mortality. Even in patients aged ≥80 years, attention should focus on the long-term oncological results, after appropriate assessment of the preoperative risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Surgery of Colorectal Carcinoma in Patients Aged over 80

Falch¹,

Kratt²,

Beckert³

et al. 2009

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…However, patients who show no evidence of metastasis to lymph nodes may still go on to develop metastatic spread. Therefore the anticancer effects of Cox‐2 inhibitors could be exploited for all patients undergoing colonic and rectal cancer surgery, as a prophylactic treatment against disease recurrence98. This type of strategy has been employed for other cancers, such as those of the breast and prostate, in which hormonal manipulations with tamoxifen and antiandrogen therapies have played a role in clinical practice99, 100.…”

Section: Potential Clinical Therapeutic Applicationsmentioning

confidence: 99%

Cyclo-oxygenase 2 inhibition in colorectal cancer therapy

Church

Fleshman

McLeod

2003

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…In most patients, colorectal cancer develops from benign adenoma over many years [2,3]. However, 70% of all colorectal cancer patients are diagnosed with a stage-III/IV disease, and only a minority of these patients can expect to be successfully treated by surgery and adjuvant therapy [4,5].…”

Section: Introductionmentioning

confidence: 99%

Detection of colorectal adenoma and cancer based on transthyretin and C3a‐desArg serum levels

Fentz

Spörl

Spangenberg

et al. 2007

Proteomics Clinical Apps

View full text Add to dashboard Cite

Colorectal cancer is the second leading cause of cancer death, and it develops from benign colorectal adenomas in over 95% of patients. Early detection of these cancer precursors by screening tests and their removal can potentially eradicate more than 95% of colorectal cancers before they develop. To discover sensitive and specific biomarkers for improvement of pre-clinical diagnosis of colorectal adenoma and cancer, we analysed in two independent studies (n = 87 and n = 83 patients) serum samples from colorectal cancer (stage III), colorectal adenoma and control patients using SELDI-TOF-MS. Extensive statistical analysis was performed to establish homogeneous patient groups based on their clinical data. Two biomarkers that were each able to distinguish control patients from either colorectal adenoma or colorectal cancer patients (p<0.001) were identified as transthyretin (pre-albumin) and C3a-desArg by MS/MS and were further validated by antibody-based assays (radial immunodiffusion, ELISA). A combination of both proteins clearly indicated the presence of colorectal adenoma or carcinoma. Using a cut-off of <0.225 g/L for transthyretin and >1974 ng/mL for C3a-desArg, we found a sensitivity and specificity for colorectal adenoma of 96% and 70%, respectively.

show abstract

Adjuvant chemotherapy for colorectal cancer

Cited by 12 publications

References 46 publications

Surgery of Colorectal Carcinoma in Patients Aged over 80

Surgery of Colorectal Carcinoma in Patients Aged over 80

Cyclo-oxygenase 2 inhibition in colorectal cancer therapy

Detection of colorectal adenoma and cancer based on transthyretin and C3a‐desArg serum levels

Contact Info

Product

Resources

About